Cargando…

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

BACKGROUND: The results of recent studies suggest that dipeptidyl‐peptidase‐4 inhibitors have antiatherogenic effects. However, whether or not dipeptidyl‐peptidase‐4 inhibitors could suppress arterial inflammation and intimal hyperplasia after injury remains undetermined. The present study aims to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akita, Koji, Isoda, Kikuo, Shimada, Kazunori, Daida, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392431/ https://www.ncbi.nlm.nih.gov/pubmed/25770025 http://dx.doi.org/10.1161/JAHA.114.001469

Ejemplares similares

Lack of IκBNS promotes cholate-containing high-fat diet-induced inflammation and atherogenesis in low-density lipoprotein (LDL) receptor-deficient mice
por: Kitamura, Kenichi, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
por: Liu, Xu, et al.
Publicado: (2021)

An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice
por: Akita, Koji, et al.
Publicado: (2017)

Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
por: Zhang, Xiaowei, et al.
Publicado: (2017)

Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis
por: Sato-Okabayashi, Yayoi, et al.
Publicado: (2020)

Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study
por: Takamiya, Yosuke, et al.
Publicado: (2020)

Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice
por: Yano, Wataru, et al.
Publicado: (2016)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Different responses to oxidized low-density lipoproteins in human polarized macrophages
por: Hirose, Kuniaki, et al.
Publicado: (2011)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
por: Kurozumi, Akira, et al.
Publicado: (2013)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
por: Joo, Kwon Wook, et al.
Publicado: (2013)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Voluntary exercise and cardiac remodeling in a myocardial infarction model
por: Shahi, Hamad Al, et al.
Publicado: (2020)

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
por: Masuda, Daisaku, et al.
Publicado: (2018)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Possible Role of NADPH Oxidase 4 in Angiotensin II-Induced Muscle Wasting in Mice
por: Kadoguchi, Tomoyasu, et al.
Publicado: (2018)

Mathematical Model for Low Density Lipoprotein (LDL) Endocytosis by Hepatocytes
por: Wattis, J. A. D., et al.
Publicado: (2008)

Thrombolytic Therapy and Aspiration of Clots were Effective in the Removal of a Transient Inferior Vena Cava (IVC) Filter that Captured a Large Thrombus
por: Takahashi, Norihito, et al.
Publicado: (2017)

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
por: Nojima, Hiroyuki, et al.
Publicado: (2016)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das, Siddhartha Shankar, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vie797712boitdgc8narsj9fl